United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $300.31, for a total transaction of $3,303,410.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at $11,045,702.11. This trade represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $297.68 on Tuesday. The company has a 50 day simple moving average of $301.04 and a 200 day simple moving average of $319.73. The firm has a market cap of $13.43 billion, a PE ratio of 11.88, a price-to-earnings-growth ratio of 6.46 and a beta of 0.53. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the business earned $6.17 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in United Therapeutics by 43.3% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 312 shares during the last quarter. Bank & Trust Co raised its holdings in United Therapeutics by 3.9% during the 2nd quarter. Bank & Trust Co now owns 1,371 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 52 shares during the last quarter. Park Avenue Securities LLC raised its holdings in United Therapeutics by 1.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 39 shares during the last quarter. Sowell Financial Services LLC bought a new position in United Therapeutics during the 2nd quarter worth approximately $333,000. Finally, Diversified Trust Co raised its holdings in United Therapeutics by 73.1% during the 2nd quarter. Diversified Trust Co now owns 3,188 shares of the biotechnology company’s stock worth $916,000 after purchasing an additional 1,346 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on UTHR shares. UBS Group decreased their price target on shares of United Therapeutics from $410.00 to $385.00 and set a “buy” rating on the stock in a research note on Monday, June 30th. Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $383.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.